The latest analyst coverage could presage a bad day for BridgeBio Pharma, Inc. (NASDAQ:BBIO), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders ...
Source LinkThe latest analyst coverage could presage a bad day for BridgeBio Pharma, Inc. (NASDAQ:BBIO), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders ...
Source Link
Comments